TSA-DC Vaccine in Treating Patients With Gastrointestinal Solid Tumor

August 11, 2017 updated by: BGI, China

Study of DC Vaccine Loaded Tumor Specific Antigen in Treating Patients With Gastrointestinal Solid Tumor

The goal of this study is to learn about the safety and tolerance of autologous TSA-DC cell and evaluate the efficacy and feasibility of the cell therapy compared to the patients' past standard regimen. 20 gastrointestinal solid tumors subjects failed from at least one systemic therapy will be enrolled into the trial and receive a succession of treatment of TSA-DC vaccine.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

20 gastrointestinal solid tumor subjects failed from at least one systemic therapy will be enrolled into the trial .Subjects will be given subcutaneous injection of 5.0x10^6-1.0x10^7 TSA-DC on week 1, 3, 5, 11,17,23,35,47. Before the first cell infusion, the subjects should undergo a non-myeloablative chemotherapy regimen of Cyclophosphamide 300mg/m2 iv. Radiologic tumor assessment will be repeated every 8 weeks during treatment, until time of progression. Treatment will continue until disease progression, intolerance of toxic , withdrawal from the study, study completion, or study termination.

Study Type

Interventional

Enrollment (Anticipated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Be ≥18 and ≤75,no gender based;
  2. Expression of HLA-A0201/1101/2402;
  3. Histopathologic documentation of gastrointestinal solid tumors(stomach cancer or colorectal cancer ) concurrent with the diagnosis of metastatic disease, and the tumor is Measurable;
  4. Patients must have adequate tissue (fresh or paraffin block) for DNA extraction, which is used for gene sequencing, and prognoses the tumor specific antigen in turn,can predict to have new tumor antigens with high affinity for MHC molecules;
  5. Failure in conventional treatment， or though benefit from chemotherapy the patient can't tolerant subjectively;
  6. Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 and an anticipate life expectancy of at least three months,be cooperate to adverse reactions monitoring and therapeutic evaluation of the treatment;
  7. Participants of child-bearing potential must agree to use adequate contraceptive methods up to 12 months after the pretreatment;
  8. Serology：Seronegative for HIV antibody,seronegative for hepatitis C antibody. Hematology：Absolute neutrophil count ≥ 1000/mm(3) without the support of filgrastim ,WBC ≥ 3000/mm(3)，lymphocyte count ≥ 800/mm(3)，Platelet count ≥ 100,000/mm(3)，Hemoglobin ≥ 9.0 g/dl Chemistry：Serum ALT/AST ≤ 2.5 times the upper limit of normal，Serum Creatinine ≤1.6 mg/dl，Total bilirubin < 1.5 mg/dl, except in patients with Gilbert s Syndrome who must have a total bilirubin < 3.0 mg/dl;
  9. Patients or their legal representatives are willing and able to understand and written informed consent form for the trial;

Exclusion Criteria:

  1. Is pregnant or breastfeeding,or expecting to conceive;
  2. Have a history of severe immediate hypersensitivity reaction to any of the agents used in this study.
  3. Suffered grade 3-4 major organ immune-related adverse events after anti-PD1/PDL1 antibody treatment.
  4. Once received allogeneic organ transplantation (including bone marrow transplantation and peripheral stem cell transplantation, except for corneal transplantation);
  5. Have clinical symptoms of central nervous system metastases;
  6. Have used a large number of glucocorticoids or other immunosuppressive agents within 4 weeks;
  7. Have any active autoimmune disease ;
  8. Be in active infection or undergo an unknown cause fever> 38.5 ℃ during screening or before the first administration(except tumor fever which evaluated by the researchers have no effect to enrollment );
  9. Received chemotherapy or small molecule targeted drug therapy in 4 weeks prior to chemotherapy pretreatment;
  10. Received any antibody drug therapy (including PD-1 and CTLA-4) within 6 weeks before the treatment period;
  11. Severe liver and kidney dysfunction or uncontrollable diabetes, hypertension and other chronic systemic diseases; severe coagulation disorders, mental illness, cardiopulmonary disease，hydrothorax or ascites;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental

Drug:Cyclophosphamide

Biological/Vaccine:Tumor Specific Antigen-loaded Dendritic Cells
Biological: Tumor Specific Antigen-loaded Dendritic Cells
Subjects will be given subcutaneous injection of 5.0x10^6-1.0x10^7 TSA-DC on week 1,3,5,11,17,23,35,47.
Other Names:
  • TSA-DC vaccine
Drug: Cyclophosphamide
300 mg/m2 by vein before the first cell infusion.
Other Names:
  • Cytoxan

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
safety endpoint
Time Frame: one year
All the local or systemic reactions, adverse events and serious adverse events that occurred between the first and the second TSA-DC administration.
one year
Overall Response Rate
Time Frame: one year
Percentage of cases whose tumor shrinks to a certain extent and remains for a certain period of time.
one year
Proportion of the number of cases that has produced tumor-specific antigen-specific T cells in peripheral blood.
Time Frame: one year
one year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Secondary safety endpoint
Time Frame: one year
All local or systemic reactions, adverse events and serious adverse events that occurred from entering the trial until 30 days after the last treatment;
one year
Six month DCR(CRR+PRR+SDR)
Time Frame: 6 month
Percentage of cases with no progression (CR + PR + SD) in 6 months after initiation of treatment;
6 month
Duration of Response(DOR)
Time Frame: one year
The time from the first tumor evaluation of remission(CR + PR ) till the first assessment of PD or the end the study.
one year
Progression-free survival(PFS)
Time Frame: one year
The time from entering the trial till the subject has been diagnosed with progression of disease or died.
one year
rate of 12-month survival
Time Frame: one year
Percentage of cases with 12 months survival after initiation of treatment in all the subjects;
one year
Quality score of life improvement
Time Frame: one year
Evaluated by the questionnaire of life improvement quality collected from the screening to treatment periods.
one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

BGI, China

Collaborators

Fujian Cancer Hospital

Investigators

  • Principal Investigator: ZengQing Guo, Professor, Fujian Cancer Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

December 1, 2017

Primary Completion (Anticipated)

December 1, 2018

Study Completion (Anticipated)

June 1, 2019

Study Registration Dates

First Submitted

June 11, 2017

First Submitted That Met QC Criteria

June 12, 2017

First Posted (Actual)

June 14, 2017

Study Record Updates

Last Update Posted (Actual)

August 14, 2017

Last Update Submitted That Met QC Criteria

August 11, 2017

Last Verified

August 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BGI-002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tumor Gastric

Clinical Trials on Tumor Specific Antigen-loaded Dendritic Cells

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe